DiaMonTech AG

DiaMonTech AG postpones IPO

DiaMonTech AG: DAK-Gesundheit and DiaMonTech plan strategic cooperation in the non-invasive blood glucose monitoring sector for new treatment strategies in the diabetes sector

DiaMonTech: First-time product presentation of the ‘D-Base’ at the world-wide largest medical technology trade fair COMPAMED/MEDICA 2019

DiaMonTech announces price range for IPO

DiaMonTech sets price range for IPO at 32.00 euros to 38.00 euros per share

DiaMonTech strengthens its international distribution network – Agreement signed for the distribution of at least 40,000 ‘D-Pocket’ devices in Latin America

DiaMonTech plans IPO to finance growth

DiaMonTech: Successful clinical study confirms breakthrough in the development of non-invasive blood glucose monitoring

DiaMonTech selected as one of Europe’s best deep tech scaleups at the EIT Digital Challenge 2019

DiaMonTech wins Enrico Just as Managing Director and CFO

DiaMonTech: Innovative, pain-free blood glucose monitoring to improve the quality of life of diabetes patients in Germany with the help of local pharmacies

DiaMonTech successfully concludes financing round of more than 7 million Euro

DiaMonTech’s first product ‘DMT Base’ receives CE-certification for non-invasive blood glucose monitoring with laser-based technology